1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Biologics Development
  6.  » Accelerating Manufacturing for Investigational COVID-19 Therapeutic Candidate Lenzilumab

 Accelerating Manufacturing for Investigational COVID-19 Therapeutic Candidate Lenzilumab

Summary: There is steadily increasing momentum in the pharmaceutical industry to accelerate speed to market, driven by the desire to get therapies to patients as soon as possible and enabled by regulatory authorities through implementation of accelerated review pathways. The COVID-19 pandemic has highlighted this need to compress timelines in order to address this public health crisis.

During this presentation, Cameron Durrant, M.D., MBA, Chairman and Chief Executive Officer, Humanigen, and Melanie Lasher, Manager, Project Management, Catalent Biologics present a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials, including how the two companies have collaborated to address the challenge of manufacturing scale up to get lenzilumab to patients as quickly as possible.

 

Click here to download the Webinar